Pyrotinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HER2-positive advanced or metastatic breast cancer with capecitabine after anthracycline... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:HER2-Positive Breast Cancer · Phase 3 · investigational in the US

Also approved (1)
CN
  • HER2-positive advanced or metastatic breast cancer with capecitabine after anthracycline or taxane (conditional approval); full second-line approval July 2020
Product first approved 20181stoncology.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (19)
HER2-Positive Breast Cancer
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
NCT05910398 · RenJi Hospital
2023-06-01 – 2030-08 · Breast Cancer Invasive
What this study did
NCT07615751 · Fudan University
2025-02-12 – 2029-12-30 · Breast Cancer
What this study did
NCT04254263 · RenJi Hospital
2019-12-16 – 2028-08 · Locally Advanced Breast Cancer
What this study did
NCT05346861 · Fudan University
2021-09-15 – 2024-10-31 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT03588091 · Jiangsu HengRui Medicine Co., Ltd.
2018-07-24 – 2024-01-31 · HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05841381 · Fudan University
2023-05-06 – 2033-05-06 · Breast Cancer
What this study did
NCT06278870 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-09-06 – 2031-06-30 · HER2-positive Metastatic Breast Cancer, First-line Treatment
What this study did
NCT06144944 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-17 – 2031-01-31 · Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
What this study did
NCT04646759 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-10-14 – 2030-12-14 · Breast Cancer
What this study did
NCT07797218 · Shanghai Jiao Tong University School of Medicine
2026-07-01 – 2030-06-30 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT07528716 · Fudan University
2026-05-06 – 2028-06 · Breast Cancer
What this study did
NCT04973319 · Shengjing Hospital
2021-08-01 – 2027-08-01 · Breast Cancer
What this study did
NCT03980054 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-12 – 2027-06 · Breast Cancer
What this study did
NCT03863223 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-22 – 2024-07-30 · Metastatic Breast Cancer
What this study did
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
NCT02973737 · Jiangsu HengRui Medicine Co., Ltd.
2016-07-20 – 2023-06 · HER2 Positive Metastatic Breast Cancer
What this study did
Phase 2/3 (4)
HER2-Positive Breast Cancer
NCT06958627 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-04-30 – 2027-04-30 · HER2 Positive Breast Cancer, Pyrotinib Treatment
What this study did
Other / comorbidity
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04290793 · Hebei Medical University Fourth Hospital
2020-03-01 – 2026-12-10 · Breast Cancer
What this study did
Phase 2 (118)
HER2-Positive Breast Cancer
NCT06973525 · Hebei Medical University Fourth Hospital
2025-09-01 – 2032-05-31 · HER2-positive Breast Cancer
What this study did
NCT07766772 · Fujian Cancer Hospital
2026-09-30 – 2031-12-31 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT07019337 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-06-30 – 2030-12-31 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04158856 · xuexin he
2020-06-01 – 2030-05-31 · HER2-positive Breast Cancer
What this study did
NCT05635487 · Shengjing Hospital
2023-03-16 – 2030-02-28 · HER2-positive Breast Cancer
What this study did
NCT06832904 · First Affiliated Hospital of Zhejiang University
2024-12-03 – 2030-01 · HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT07635342 · Hebei Medical University Fourth Hospital
2024-04-30 – 2029-12-31 · HER2-positive Breast Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05834764 · The First Affiliated Hospital with Nanjing Medical University
2023-04-08 – 2028-12-31 · HER2-positive Breast Cancer
What this study did
NCT07132242 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-08-30 – 2028-12-31 · Metastatic Breast Cancer With HER2 Positive
What this study did
NCT04398914 · Shanghai Jiao Tong University School of Medicine
2020-05-30 – 2027-12-30 · Breast Cancer Invasive
What this study did
NCT04481932 · Peking University
2020-07 – 2026-12 · HER2-positive Breast Cancer
What this study did
NCT04126525 · RenJi Hospital
2019-06-18 – 2026-11 · Breast Cancer Female
What this study did
NCT04659499 · Peking Union Medical College Hospital
2021-01-01 – 2026-05-15 · Early Breast Cancer
What this study did
NCT05880927 · Taizhou Hospital
2019-01-01 – 2025-12-31 · Breast Cancer
What this study did
NCT06152822 · Tongji Hospital
2023-11-30 – 2025-11-30 · Breast Cancer With Brain Metastases
What this study did
NCT05430347 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-09-30 · Breast Cancer
What this study did
NCT04858516 · Guangdong Provincial People's Hospital
2021-04-30 – 2025-04-30 · Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
What this study did
NCT05255523 · Fujian Medical University Union Hospital
2022-02-20 – 2024-12-20 · Advanced Breast Cancer
What this study did
NCT04997798 · First Affiliated Hospital of Zhejiang University
2022-09-01 – 2024-12 · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
What this study did
NCT05429294 · First Affiliated Hospital Xi'an Jiaotong University
2022-06-01 – 2024-10-30 · HER2-positive Breast Cancer
What this study did
NCT05076695 · Fudan University
2021-10-15 – 2024-10-15 · Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03910712 · Peking Union Medical College Hospital
2019-06-01 – 2023-12-01 · Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
What this study did
NCT04605575 · Sun Yat-sen University
2020-05-22 – 2023-12-01 · Breast Cancer, Pyrotinib, Breast Diseases, Vinorelbine, HER2-positive Breast Cancer
What this study did
NCT04088110 · Fuzhou General Hospital
2019-11 – 2023-11 · Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
What this study did
NCT04236310 · Ruijin Hospital
2020-01-15 – 2022-12-31 · Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer
What this study did
NCT04095390 · Jinming Yu
2019-09-30 – 2022-08-30 · Metastatic Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03919253 · Hebei Medical University Fourth Hospital
2019-04-30 – 2022-04-30 · HER2-positive Breast Cancer
What this study did
NCT04639271 · Shandong Cancer Hospital and Institute
2021-01-01 – 2022-03-01 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT04033172 · Chinese Academy of Medical Sciences
2018-11-01 – 2021-09-01 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03735966 · Henan Cancer Hospital
2018-11-20 – 2020-10-20 · HER2 Positive Breast Cancer
What this study did
NCT04066790 · Shanghai Jiao Tong University School of Medicine
2019-09-09 – 2020-04-30 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06563999 · Sun Yat-sen University
2024-11-01 – 2029-11-01 · Lung Cancer Stage III, Mutation
What this study did
NCT05751018 · Peking Union Medical College Hospital
2021-12-08 – 2026-12-31 · Non-small Cell Lung Cancer
What this study did
NCT06185400 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-02-01 – 2026-12-01 · Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
What this study did
NCT04144569 · Yongchang Zhang
2019-01-30 – 2024-12-31 · HER2 Insertion Mutation Positive Advanced NSCLC
What this study did
NCT03574402 · Guangdong Association of Clinical Trials
2018-07-09 – 2024-12-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04382300 · Shanghai Chest Hospital
2020-06-30 – 2023-04 · Non-small-cell Lung Cancer
What this study did
NCT04706949 · Fudan University
2020-12-07 – 2022-12-31 · Lung Cancer, Non-small Cell
What this study did
NCT04063462 · Tianjin Medical University Cancer Institute and Hospital
2019-10-01 – 2021-10-01 · Non Small Cell Lung Cancer
What this study did
NCT02834936 · Jiangsu HengRui Medicine Co., Ltd.
2016-10-20 – 2019-06-20 · Non Small Cell Lung
What this study did
NCT02535507 · Tongji University
2015-01 – 2017-12 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07393425 · Shanghai Jiao Tong University School of Medicine
2026-02-02 – 2032-09-30 · HER2 + Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06692491 · Peking University Shenzhen Hospital
2025-01-01 – 2029-12-31 · Rare Tumour
What this study did
NCT07014410 · Zhejiang Cancer Hospital
2023-02-01 – 2029-12-31 · Breast Cancer
What this study did
Phase 1/2 (14)
HER2-Positive Breast Cancer
NCT05575804 · Fudan University
2022-10-01 – 2028-12-31 · Advanced/ Metastatic Her-2 Positive Breast Cancer
What this study did
NCT07708194 · Tianjin Medical University Cancer Institute and Hospital
2025-06-23 – 2027-02 · Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04582968 · Fudan University
2020-01-02 – 2023-08-12 · Breast Cancer, Brain Metastases, HER2-positive Breast Cancer
What this study did
NCT04152057 · West China Hospital
2019-11 – 2021-04 · Breast Cancer, HER2 Positive, Combination Chemotherapy
What this study did
Non-Small Cell Lung Cancer
NCT05745740 · RemeGen Co., Ltd.
2027-12-01 – 2028-12-01 · Non-small Cell Lung Cancer
What this study did
NCT05482568 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2026-12 · Advanced Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07189884 · The First Affiliated Hospital of Xiamen University
2025-09-23 – 2028-12-31 · Locally Advanced Breast Cancer (LABC)
What this study did
NCT06718933 · Fudan University
2025-01-08 – 2027-02-28 · Breast Cancer Metastatic, Breast Cancer Brain Metastases
What this study did
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT06015048 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-11 – 2026-12-29 · HER2-expressing Advanced Solid Tumors
What this study did
NCT03772353 · Fudan University
2019-05-12 – 2025-12-10 · Breast Cancer
What this study did
NCT04227041 · Qingdao Zhixin Health Technology Co., Ltd.
2020-01-10 – 2023-01-10 · HER-2 Positive Colorectal Cancer
What this study did
NCT03805399 · Fudan University
2018-10-18 – 2022-12-01 · Triple-negative Breast Cancer
What this study did
NCT02422199 · Jiangsu HengRui Medicine Co., Ltd.
2015-05 – 2018-12 · HER2 Positive Metastatic Breast Cancer
What this study did
Phase 1 (12)
Non-Small Cell Lung Cancer
NCT02500199 · Hengrui Therapeutics, Inc.
2015-06 – 2021-06 · Breast Cancer, Gastric Cancer, Solid Tumors, NSCLC
What this study did
Other / comorbidity
NCT06770296 · The First Affiliated Hospital with Nanjing Medical University
2024-11-01 – 2028-11-01 · Breast Cancer
What this study did
NCT04367090 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-28 – 2023-05-24 · Metastatic Breast Cancer
What this study did
NCT05252546 · Jiangsu HengRui Medicine Co., Ltd.
2022-03-08 – 2022-08-02 · HER2-positive Recurrent / Metastatic Breast Cancer
What this study did
NCT04680091 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-12 – 2021-12-30 · Healthy Subjects, Drug-drug Interaction, Pyrotinib
What this study did
NCT04850651 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-16 – 2021-05-17 · Healthy Subjects
What this study did
NCT04315116 · Jiangsu HengRui Medicine Co., Ltd.
2020-04-13 – 2020-09-01 · Healthy Participants
What this study did
NCT04315493 · Jiangsu HengRui Medicine Co., Ltd.
2020-03 – 2020-04 · Healthy Participants
What this study did
NCT04479891 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-18 – 2019-11-30 · Healthy Subjects
What this study did
NCT02378389 · Jiangsu HengRui Medicine Co., Ltd.
2014-09 – 2017-08 · HER2 Positive Gastric Cancer
What this study did
NCT02361112 · Jiangsu HengRui Medicine Co., Ltd.
2014-08 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT01937689 · Jiangsu HengRui Medicine Co., Ltd.
2013-01 – 2016-12 · Breast Cancer
What this study did
Phase 4 (4)
HER2-Positive Breast Cancer
NCT07600164 · Peking University People's Hospital
2026-07-06 – 2031-12-30 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT04929548 · Wuhan University
2022-01-05 – 2027-09-20 · Breast Cancer
What this study did
NCT06217185 · Hebei Medical University Fourth Hospital
2024-01-02 – 2027-06-30 · HER2-positive Breast Cancer, Advanced Breast Cancer
What this study did
Other / comorbidity
NCT06245824 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01-30 – 2026-12-01 · Breast Cancer
What this study did
Early phase / not applicable (10)
HER2-Positive Breast Cancer
NCT06718335 · Nie Jianyun
2024-12-30 – 2029-12-30 · HER2-positive Breast Cancer
What this study did
NCT06015113 · Xi'an International Medical Center Hospital
2023-09 – 2027-04 · Breast Cancer
What this study did
NCT06035679 · Youzhi Zhu
2023-08-17 – 2026-11-30 · Breast Cancer Female
What this study did
NCT03756064 · Zhejiang Cancer Hospital
2019-08-01 – 2021-07-31 · Breast Cancer, Neoplasm, Breast, Breast Diseases
What this study did
NCT03847818 · Shandong University
2019-03-01 – 2021-02-28 · HER2-positive Breast Cancer
What this study did
NCT03947242 · Henan Cancer Hospital
2019-06-01 – 2020-12-30 · HER2 Positive Breast Cancer
What this study did
Other / comorbidity
NCT06495541 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2028-07-30 · Breast Cancer, RWS, Pyrotinib
What this study did
NCT05560308 · Tianjin Medical University Cancer Institute and Hospital
2022-09-30 – 2025-08-23 · HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
What this study did
NCT03843749 · Shanghai Changzheng Hospital
2019-07-01 – 2022-07-01 · Colorectal Cancer
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Other / comorbidity
NCT05424835 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-04 – 2027-12-31 · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
What this study did
NCT04736589 · Peking Union Medical College
2021-02-02 – 2027-02-02 · Breast Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pyrotinib: this drugPhase 3Small moleculeEGFR/HER1, HER2, HER4Partial signalNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 2/3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 70 furthest-along competitors are listed; 540 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(46 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pyrotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (2)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerRecruiting
Est. primary completion 2026-11-30 · NCT06035679 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2/3Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04290793 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05751018 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT07635342 · CT.gov ↗
What to watch
2027 (16)
February 2027 (2)
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-02 · NCT07708194 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT04973319 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsRecruiting
Est. primary completion 2027-08-15 · NCT04983121 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HER2 + Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
December 2027 (7)
Phase 3Breast CancerRecruiting
Est. primary completion 2027-12 · NCT07528716 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT06718335 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (15)
January 2028 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-01 · NCT06832904 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsActive not recruiting
Est. primary completion 2028-01-01 · NCT05328440 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-05-06 · NCT05841381 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Breast Cancer Early Stage Breast Cancer (Stage 1-3)Recruiting
Est. primary completion 2028-06-30 · NCT07797218 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07019337 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2028-09 · NCT07180082 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07836257 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗
What to watch
December 2028 (5)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT07615751 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05575804 · CT.gov ↗
What to watch
Phase 2HER2-positive Early Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-04 · NCT05910398 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
Phase 2Advanced Digestive System TumorNot yet recruiting
Est. primary completion 2030-12-31 · NCT07053150 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07892274 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting
Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗
What to watch
December 2031 (2)
Phase 4HER2-Positive Breast CancerRecruiting
Est. primary completion 2031-12-30 · NCT07600164 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗
What to watch

See the full readout calendar ↗